Tempus AI, Inc. Class A Common Stock Earnings Recaps
Q1 2026
May 7, 2026
Tempus AI’s shares dropped 4.1% following the earnings report, driven by cautious outlook signals despite solid revenue growth. Investor concerns likely centered on deceleration in hereditary diagnostics and tempered margin expectations implicit in the adjusted EBITDA guidance.
Key takeaways
- Revenue of $348.1 million grew 36% year-over-year, supported by Oncology unit growth of ~28% and strong performance in solid tumor, liquid biopsies, and MRD volumes.
- Hereditary diagnostics growth slowed significantly, attributed to difficult prior-year comparables, with expectations of mid-teen growth returning only in the second half of the year.
- Data and applications revenue reached $87 million, up 40.5%, led by data licensing and modeling insights growing over 44%, with third consecutive quarter of bookings above $100 million.
- Guidance was raised to $1.59-1.6 billion in revenue for the full year with adjusted EBITDA around $65 million, implying margin pressure and more cautious profitability targets.
- Commentary highlighted solid large pharma collaborations, including new strategic deals with Merck and Gilead, yet did not fully offset investor wariness of growth pacing and margin trajectory.
Q3 2025
Nov 5, 2025
Tempus AI reported a strong Q3 2025, achieving robust growth in both Genomics and Data Licensing, culminating in the company’s first positive adjusted EBITDA.
Key takeaways
- Genomics volume surged 33% overall, with notable growth in Hereditary (37%) and Oncology (27%).
- The Data Licensing segment grew 38%, adding $150 million in total contract value.
- Achieved positive adjusted EBITDA for the first time, a significant milestone after 10 years, despite expenses from the Paige acquisition.
- Growth is underpinned by improved sales efficiency and advancements in their integrated technology offerings.
- Adjusted EBITDA for the full year is now expected to be slightly positive, even accounting for additional costs from acquisitions.